Literature DB >> 11307811

Pulmonary fibrosis is increased in mice carrying the factor V Leiden mutation following bleomycin injury.

Z Xu1, R J Westrick, Y C Shen, D T Eitzman.   

Abstract

Increased fibrin deposition following inflammatory lung injury has been proposed to facilitate the development of pulmonary fibrosis. Therefore, factors predisposing to thrombosis may affect the fibrotic response to injury. Activated protein C (aPC) resistance due to the factor V Leiden mutation (FvL) is a common genetic risk factor for vascular thrombosis. To examine the relationship between aPC resistance and the development of pulmonary fibrosis, lung inflammation was induced by bleomycin in mice carrying the FvL mutation. Three weeks following the instillation of 0.0375 U of bleomycin, the lungs of mice homozygous and heterozygous for FvL contained significantly more hydroxyproline (35 +/- 4 and 36 +/- 7 ug hydroxyproline/mg total protein, respectively) than wild-type mice (26 +/- 6 ug/mg protein, p <0.01 for both comparisons). These data demonstrate a strong relationship between aPC resistance and the pulmonary fibrosis that occurs following inflammatory lung injury.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11307811

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

1.  What is the impact of resistance to activated protein C (Leiden mutation to factor V) in inflammatory bowel disease?

Authors:  Emma Attvall; Attila Frigyesi; Berit Sternby
Journal:  Int J Colorectal Dis       Date:  2006-01-13       Impact factor: 2.571

2.  Resistance to activated protein C is a risk factor for fibrostenosis in Crohn's disease.

Authors:  Gottfried Novacek; Wolfgang Miehsler; Julia Palkovits; Walter Reinisch; Thomas Waldhör; Stylianos Kapiotis; Alfred Gangl; Harald Vogelsang
Journal:  World J Gastroenterol       Date:  2006-10-07       Impact factor: 5.742

3.  Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection.

Authors:  M Wright; R Goldin; S Hellier; S Knapp; A Frodsham; B Hennig; A Hill; R Apple; S Cheng; H Thomas; M Thursz
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

Review 4.  What we should know about portal vein thrombosis in cirrhotic patients: a changing perspective.

Authors:  Francesca Romana Ponziani; Maria Assunta Zocco; Matteo Garcovich; Francesca D'Aversa; Davide Roccarina; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2012-09-28       Impact factor: 5.742

Review 5.  Thrombin activation and liver inflammation in advanced hepatitis C virus infection.

Authors:  Emilio González-Reimers; Geraldine Quintero-Platt; Candelaria Martín-González; Onán Pérez-Hernández; Lucía Romero-Acevedo; Francisco Santolaria-Fernández
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

6.  Factor V Leiden mutation triggering four major complications to standard dose cisplatin-chemotherapy for testicular seminoma: a case report.

Authors:  Klaus-Peter Dieckmann; Petra Anheuser; Ralf Gehrckens; Sven Philip Aries; Raphael Ikogho; Wiebke Hollburg
Journal:  BMC Urol       Date:  2015-03-17       Impact factor: 2.264

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.